Cargando…
An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
There are now 9 available FDA-approved second-generation long-acting injectable antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone (2). These high-cost medications are commonly used with the goal of improving adherence and patient outcomes. With almost 2 dec...
Autor principal: | VandenBerg, Amy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Psychiatric Pharmacists
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645288/ https://www.ncbi.nlm.nih.gov/pubmed/36405505 http://dx.doi.org/10.9740/mhc.2022.10.270 |
Ejemplares similares
-
Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”
por: VandenBerg, Amy M.
Publicado: (2023) -
Comment on “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”
por: Still, Daniel, et al.
Publicado: (2023) -
Management of serious cardiac adverse effects of antipsychotic medications
por: Stoner, Steven C.
Publicado: (2018) -
Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome
por: DeJongh, Beth M.
Publicado: (2021) -
Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing
por: Stutzman, Danielle L.
Publicado: (2021)